Conference Reports for NaTaP

EASL - The International Liver Congress 2015 50th annual Meeting of the European association for the Study of the Liver Vienna, austria  april 22-26 Back

Harvoni Post-Transplant       EASL: Ledipasvir/Sofosbuvir With Ribavirin for the Treatment of Fibrosing Cholestatic Hepatitis C After Liver Transplantation - (05/04/15)   EASL: Ledipasvir/Sofosbuvir With Ribavirin is Safe and Efficacious in Decompensated and Post-Liver Transplantation Patients With HCV Infection: Preliminary Results of the SOLAR-2 Trial - (04/24/15)   EASL: Ledipasvir/Sofosbuvir With Ribavirin Is Safe in >600 Decompensated and Post-Liver Transplantation Patients With HCV Infection: An Integrated Safety Analysis of the SOLAR-1 and SOLAR-2 Trials - (04/29/15)   EASL: Early Viral Kinetics in Patients With Varying Degrees of Fibrosis and Cirrhosis in the SOLAR-1 Trial - (05/04/15)   EASL: All Oral HCV Therapy is Safe and Effective in Patients with Decompensated Cirrhosis: Report from HCV-TARGET - (04/23/15)   EASL - The International Liver Congress 2015 50th Annual Meeting of the European Association for the Study of the Liver Vienna, Austria April 22-26